CD274 and non-small cell lung carcinoma: However, a phase 1 clinical trial testing PD-L1 CAR-T cell therapy in NSCLC resulted in a serious adverse event of pulmonary toxicity that occurred 47 days after infusion of CAR-T cells [77].